NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer
Despite the success of immune checkpoint inhibition (ICI) in treating cancer, patients with
triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying …
triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying …
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
L Licata, MV Dieci, C De Angelis, C Marchiò… - Cancer Treatment …, 2024 - Elsevier
Immunotherapy has revolutionized cancer therapy and now represents a standard of care
for many tumor types, including triple-negative breast cancer. Despite the positive results …
for many tumor types, including triple-negative breast cancer. Despite the positive results …
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review
J Van Cauwenberge, K Van Baelen, M Maetens… - Breast Cancer …, 2024 - Springer
Background The proportion of patients with breast cancer and obesity is increasing. While
the therapeutic landscape of breast cancer has been expanding, we lack knowledge about …
the therapeutic landscape of breast cancer has been expanding, we lack knowledge about …
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven't Found What We're Looking For
D Quiroga, ME Gatti-Mays - JAMA oncology, 2024 - jamanetwork.com
Despite great advances in breast cancer outcomes during the last decade, the benefit of
immune checkpoint inhibitors (ICIs) remains limited to a select population of patients with …
immune checkpoint inhibitors (ICIs) remains limited to a select population of patients with …
Biomarkers in the Immuno-oncology Interface of Triple Negative Breast Cancer: A Scoping Review with Perioperative Considerations
L Smith, J Saganty, P Forget - Current Oncology Reports, 2024 - Springer
Important areas of focus for future research include a greater understanding of complex
cellular, genetic and metabolic interactions in the perioperative tumour microenvironment …
cellular, genetic and metabolic interactions in the perioperative tumour microenvironment …
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
EC Wescott, X Sun, P Gonzalez-Ericsson… - Cancer Research …, 2024 - AACR
Combinations of immune checkpoint inhibitors (ICI, including anti-PD-1/PD-L1) and
chemotherapy have been FDA approved for metastatic and early-stage triple-negative …
chemotherapy have been FDA approved for metastatic and early-stage triple-negative …
An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy
A Kwan, K Stark, R Allen, P Ottewell… - Medical Research …, 2024 - esmed.org
One of the barriers to novel treatment developments within breast cancer is the ability to
prove efficacy in the preclinical setting before moving on to clinical trials. Preclinical models …
prove efficacy in the preclinical setting before moving on to clinical trials. Preclinical models …